Clinical Trial Search

Primary: HbA1c Change From Baseline — 0.03; -0.59; -0.63 percentage of HbA1c — p=<0.0001

Primary: The Primary Efficacy Endpoint is the Change From Baseline to Week 4 of the Treatment Period in the Modified Gastroparesis Cardinal Symptom Index-Daily Diary (mGCSI-DD)…

Primary: Biological Response as Characterized by Selected Cytokines, Specifically Tumor Necrosis Factor Alpha (TNFα), Interleukin One (IL-1β), and Interleukin Six (IL-6).

Primary: Change From Baseline in HbA1c After 18 Weeks of Treatment — -0.50; -0.94; -1.02 percentage of HbA1c — p=<0.0001

Primary: HbA1c Change From Baseline — -0.11; -0.59; -0.72 percentage of HbA1c — p=<0.0001

Primary: Comparing Estradiol AUC of Menstrual Period During Study Drug Administration With Pre and Post Study Drug Administration (Baseline(BL)-Study Drug Administration(SDA)…

Primary: Total Sleep Time Measured by Actigraphy — 339.80; 304.60; 413.89; 308.89 Minutes — p=0.54

Primary: HbA1c Change From Baseline — -0.13; -0.70; -0.77; -2.78 percentage of HbA1c — p=<0.0001

Primary: Change From Baseline in the Total International Prostate Symptom Score (IPSS) at Months 1, 3, 6, 9, 12, 15, 18, 21, and 24 Using the Last Observation Carried Forward…

Primary: HbA1c Change From Baseline in Patients With Mild or Moderate Renal Impairment — 0.05; -0.46 percentage of HbA1c — p=<0.0001

Primary: Change in Apoptotic Indices Before and After Treatment — -2.99 Percentage of TUNEL positive cells

Primary: Antibody Concentrations Against Pneumococcal Serotypes During the Primary Phase of the Study — 1.54; 1.59; 1.37; 2.18 µg/mL

Primary: Change From Baseline in Glycosylated Haemoglobin (HbA1c) After 24 Weeks — 0.06; -0.66; -0.77; -0.65 percent of HbA1c — p=<0.0001

Primary: Fibrinogen Level Change — 317; 235; 331; 312 mg/dl

Primary: Percentage Change in Total AKN Lesions From Baseline to Week 16. — 49 percentage of lesion count reduction